Abstract 17698: Prevalence and Locations of Extra-cardiac Lesions on 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Suspected Cardiac Sarcoidosis
Introduction: Cardiac positron emission tomography (PET) has been reported to be useful tool for evaluating the location, extent, and activity of cardiac sarcoidosis. Sarcoidosis, which is a systemic inflammatory disorder, can often affect any other organs beyond the heart. Whole-body PET allows us to detect not only cardiac sarcoidosis, but also subclinical lesions in extra-cardiac organs. However, its prevalence and locations of extra-cardiac findings with whole-body PET is still unknown. Therefore, the aim of this study was to clarify the prevalence and location of 18F-fluorodeoxyglucose (FDG) uptake with whole-body PET in patients with suspected cardiac sarcoidosis.
Methods: We studied 124 consecutive patients with clinically suspected cardiac sarcoidosis who underwent whole-body FDG-PET imaging. After excluding those who were diagnosed as non-cardiac sarcoidosis or under steroid therapy, we finally enrolled 95 patients in this study. The prevalence and locations of extra-cardiac FDG uptakes were assessed.
Results: Thirty-four patients had cardiac FDG uptakes and 15 patients (16%) had one or more extra-cardiac FDG uptakes. Abnormal FDG uptakes related to systemic sarcoidosis disorder were observed in mediastinal lymph node (n = 12), subcutaneous lymph node (n = 6), lung (n = 5), liver (n = 2), gluteus muscle (n = 2), spleen (n = 2), and bone (n = 1). In the 5 patients who were negative for sarcoidosis by endomyocardial biopsy, sarcoidosis was confirmed histologically by PET-guided biopsy (4 subcutaneous lymph nodes, 1 gluteus muscle).
Conclusions: The prevalence of extra-cardiac lesions on whole-body FDG-PET in patients with suspected cardiac sarcoidosis was relatively high, 16%. The extra-cardiac lesions were distributed widely throughout the body. The evaluation of extra-cardiac FDG uptake with whole-body FDG-PET might provide us reliable information for pathological diagnosis with PET-guided biopsy.
Author Disclosures: C. Iio: None. H. Higashi: None. A. Ogimoto: None. H. Kawakami: None. F. Seike: None. T. Kono: None. T. Uetani: None. J. Aono: None. T. Nagai: None. K. Nishimura: None. K. Inoue: None. J. Suzuki: None. T. Okura: None. J. Higaki: None. S. Ikeda: None.
- © 2016 by American Heart Association, Inc.